| My Account | Subscribe | Contact Us | Donate |
Home
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Type 2 Issues Articles
The study results, presented at the recent ADA conference, showed that only 0.44 percent of exenatide users experienced an episode of acute pancreatitis.
Research Disputes FDA Claim that Exenatide Increase Risk of Acute Pancreatitis
In 2008, the U.S. Food and Drug Administration published strong warnings that the type 2 diabetes drug exenatide (trade name Byetta) might increase risk of acute pancreatitis, a painful inflammation of the pancreas. The FDA's action came in the wake of reports that 30 exenatide users had come down with pancreatitis and that six of them had died from the condition.
Now, however, a study published by researchers from Medco Health Solutions, Inc., says that exenatide users run no greater risk of developing pancreatitis than type 2s who take neither drug.
The study results, presented at the recent 69th Scientific Sessions of the American Diabetes Association (ADA), showed that only 0.44 percent of exenatide users experienced an episode of acute pancreatitis. Among sitagliptin users, only 0.28 percent had such episodes. Among the control group of type 2s, however, who had never taken either drug, the rate of incidence was 0.39 percent.
The study results were based on tracking the pharmacy and medical claims of 123,621 non-insulin-using type 2s for 540 days and observing which ones came down with pancreatitis:
- 9,260 patients were exenatide users
- 2,143 patients were on sitagliptin
- 112,218 patients, the control group, used neither drug but were taking a medication designed to control blood glucose
- No patient in the study had a history of pancreatitis, hepatitis or alcohol abuse
- The patients' ages ranged from 18 to 63 years
The Medco study is the first to lend scientific support to Eli Lilly and Co., Byetta's maker. Lilly has questioned the FDA's statistical reasoning, citing the extremely low percentage of pancreatitis cases associated with the drug.
For more information on the study, visit Medco
Categories: Blood Sugar, Byetta, Community, Research, Type 2 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
1 comment -
Jun 19, 2009 -
Email to a Friend
Send a link to this page to your friends and colleagues.